Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Radiation Retinopathy: early-phase trial registry
1 of 3 indexed Radiation Retinopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Radiation Retinopathy: 3 US clinical trials tracked, 1 recruiting.
Radiation Retinopathy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is The New York Eye Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition radiation-retinopathy
OPEN 1 | RECR 33% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Radiation Retinopathy lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Radiation Retinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Radiation Retinopathy is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Jaeb Center for Health Research
NCT05844982
High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
The New York Eye Cancer Center
NCT01334879
Intravitreal Aflibercept Injection for Radiation Retinopathy
Washington University School of Medicine
NCT01579760
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Radiation Retinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Radiation Retinopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Radiation Retinopathy page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Radiation Retinopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The New York Eye Cancer Center sponsors the most Radiation Retinopathy trials on record, review their full trial history before evaluating a specific study. See The New York Eye Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Radiation Retinopathy condition card totals 3 registered trials; most-linked intervention ranibizumab 2.0 mg; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.